It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Previously, we identified a subpopulation of schizophrenia (SCZ) showing increased levels of plasma pentosidine, a marker of glycation and oxidative stress. However, its causative genetic factors remain largely unknown. Recently, it has been suggested that dysregulated posttranslational modification by copy number variable microRNAs (CNV-miRNAs) may contribute to the etiology of SCZ. Here, an integrative genome-wide CNV-miRNA analysis was performed to investigate the etiology of SCZ with accumulated plasma pentosidine (PEN-SCZ). The number of CNV-miRNAs and the gene ontology (GO) in the context of miRNAs within CNVs were compared between PEN-SCZ and non-PEN-SCZ groups. Gene set enrichment analysis of miRNA target genes was further performed to evaluate the pathways affected in PEN-SCZ. We show that miRNAs were significantly enriched within CNVs in the PEN-SCZ versus non-PEN-SCZ groups (p = 0.032). Of note, as per GO analysis, the dysregulated neurodevelopmental events in the two groups may have different origins. Additionally, gene set enrichment analysis of miRNA target genes revealed that miRNAs involved in glycation/oxidative stress and synaptic neurotransmission, especially glutamate/GABA receptor signaling, were possibly affected in PEN-SCZ. To the best of our knowledge, this is the first genome-wide CNV-miRNA study suggesting the role of CNV-miRNAs in the etiology of PEN-SCZ, through effects on genes related to glycation/oxidative stress and synaptic function. Our findings provide supportive evidence that glycation/oxidative stress possibly caused by genetic defects related to the posttranscriptional modification may lead to synaptic dysfunction. Therefore, targeting miRNAs may be one of the promising approaches for the treatment of PEN-SCZ.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 Tokyo Metropolitan Institute of Medical Science, Schizophrenia Research Project, Department of Psychiatry and Behavioral Sciences, Setagaya-ku, Japan (GRID:grid.272456.0); Nihonbashi Sun Clinic, Department of Adolescent Psychiatry, Chuou-ku, Japan (GRID:grid.272456.0)
2 Nagoya University Graduate School of Medicine, Department of Psychiatry, Nagoya, Japan (GRID:grid.27476.30) (ISNI:0000 0001 0943 978X); Nagoya University Hospital, Medical Genomics Center, Nagoya, Japan (GRID:grid.437848.4) (ISNI:0000 0004 0569 8970)
3 Tokyo Metropolitan Institute of Medical Science, Schizophrenia Research Project, Department of Psychiatry and Behavioral Sciences, Setagaya-ku, Japan (GRID:grid.272456.0); Takatsuki Clinic, Tanaka-cho, Department of Psychiatry, Akishima, Japan (GRID:grid.272456.0); Tokyo Metropolitan Matsuzawa Hospital, Department of Psychiatry, Setagaya-ku, Japan (GRID:grid.417102.1)
4 Tokyo Metropolitan Institute of Medical Science, Schizophrenia Research Project, Department of Psychiatry and Behavioral Sciences, Setagaya-ku, Japan (GRID:grid.272456.0)
5 Tokyo Metropolitan Institute of Medical Science, Schizophrenia Research Project, Department of Psychiatry and Behavioral Sciences, Setagaya-ku, Japan (GRID:grid.272456.0); Takatsuki Clinic, Tanaka-cho, Department of Psychiatry, Akishima, Japan (GRID:grid.272456.0)
6 Research Center for Genome & Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Japan (GRID:grid.272456.0)
7 Tokai University School of Medicine, 143 Shimo-Kasuya, Division of Neurology, Isehara, Japan (GRID:grid.265061.6) (ISNI:0000 0001 1516 6626)
8 Nagoya University Graduate School of Medicine, Department of Psychiatry, Nagoya, Japan (GRID:grid.27476.30) (ISNI:0000 0001 0943 978X)